<DOC>
	<DOCNO>NCT02833727</DOCNO>
	<brief_summary>Aim : To compare , among patient uncontrolled moderate severe asthma , blood eosinophil level smoker non-smokers . Secondary aim : In uncontrolled moderate severe asthmatic subject , compare asthmatic smoker non-smokers : sputum eosinophils count , fractional exhale nitric oxide ( FeNO ) , pre post bronchodilator Forced expiratory volume one second ( FEV1 ) / Forced vital capacity ( FVC ) , Asthma-related quality life , asthma exacerbation year precede enrolment study , Medical direct indirect cost relate asthma year precede enrolment study , adherence asthma treatment year precede enrolment study . Methods : Cross sectional observational study . Never-smoker smoker asthmatic treat least 2 controller medication smoke history ≥10 pack/year ACQ score ≥ 1.5 point identify database RESP . Their clinical data match Régie de l'assurance médicale du Quebec ( RAMQ ) Maintenance et exploitation de données pour l'étude de la clientèle hospitalière ( MED-ECHO ) administrative database reMed ( data medication patient private health insurance ) order access data medical service , hospitalisation medication deliver pharmacy . T</brief_summary>
	<brief_title>Airway Inflammation Disease Burden Asthmatic Smokers</brief_title>
	<detailed_description>Aim : To compare , among patient uncontrolled moderate severe asthma , blood eosinophil level smoker non-smokers . Hypothesis : Uncontrolled never-smoker asthmatic ( NSA ) great level blood eosinophil uncontrolled asthmatic smoker ( AS ) ( difference blood eosinophil count least superior 100 eosinophil per μL ) . Secondary aim : In uncontrolled moderate severe asthmatic subject , compare asthmatic smoker non-smokers : sputum eosinophils count , fractional exhale nitric oxide ( FeNO ) , pre post bronchodilator FEV1 / Forced vital capacity ( FVC ) , Asthma-related quality life , asthma exacerbation year precede enrolment study , Medical direct indirect cost relate asthma year precede enrolment study , adherence asthma treatment year precede enrolment study . Methods : Cross sectional observational study . Never-smoker smoker asthmatic treat least 2 controller medication smoke history ≥10 pack/year ACQ score ≥ 1.5 point identify Quebec registry respiratory health ( RESP ) . Their clinical data match `` Régie de l'assurance médicale du Quebec '' ( RAMQ ) `` Maintenance et exploitation de données pour l'étude de la clientèle hospitalière '' ( MED-ECHO ) administrative database database medication dispense community pharmacy patient private drug insurance ( reMed ) order access data medical service , hospitalisation medication deliver pharmacy . The subject identify RESP database fulfil definition moderate severe uncontrolled asthma contact . The Asthma Control Questionnaire ( ACQ ) administer subject phone . Subjects ACQ score ≥ 1.5 point invite come research center Sacré-Coeur Hospital . During unique visit Hospital du Sacré-Coeur de Montréal , signature consent form , 80 asthmatic smoker 80 non-smoker asthmatic subject ask complete questionnaire regard asthma control ( delay telephone interview visit hospital exceed one week ) , quality life , asthma impact daily activity . FeNO measure first . They perform spirometry . Sputum induction perform obtain sputum cell count . Blood drawn obtain blood eosinophil count serum cotinine . We able compare asthmatic smoker non-smoker asthmatic : blood eosinophil count , sputum eosinophil count , FeNO , pre post bronchodilator FEV1 / FVC , asthma-related quality life , asthma exacerbation year precede enrolment study , Medical direct indirect cost relate asthma year precede enrolment study , adherence asthma treatment year precede enrolment study . Significance : Anti-interleukin 5 show effective reduce asthma exacerbation asthmatic subject eosinophilic inflammation frequent asthma exacerbation . However , smoker exclude study . It important determine burden asthma group subject term healthcare utilization productivity work , order evaluate whether may benefit type medication . If show direct indirect cost relate asthma high asthmatic smoker non-smokers , even important characterize airway inflammation group subject order determine whether likely candidate receive new biologic agent order improve asthma control , decrease healthcare utilization improve productivity work .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Participation RESP Database . Neversmoker smoker asthmatic ( smoke history ≥10 pack/year ) Treatment least 2 controller medication ACQ score ≥ 1.5 point identify database RESP . Chronic obstructive Pulmonary Disease ( COPD )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>asthma ; smoking ; Eosinophils ; health care cost</keyword>
</DOC>